Media

Corgentech Appoints Thomas Yonker Vice President of Project and Alliance Management

SOUTH SAN FRANCISCO, Calif., Apr 7, 2004 /PRNewswire-FirstCall via COMTEX/ -- Corgentech Inc. (Nasdaq: CGTK), a biotechnology company, announced today that Thomas Yonker has been appointed vice president of project and alliance management. Previously, he served as project management director for InterMune, a biopharmaceutical company.

At Corgentech, Mr. Yonker will oversee a collaboration with Bristol-Myers Squibb to jointly develop and commercialize the company's lead product candidate, E2F Decoy (edifoligide sodium). E2F Decoy is a novel and proprietary transcription factor decoy, which currently is in two Phase 3 clinical trials: one in coronary artery bypass graft (CABG) surgery, the other in peripheral (i.e., in the leg) bypass graft surgery, for the single indication of prevention of bypass graft failure. In his role, Mr. Yonker will provide project management organization and coordinate relevant staff from Corgentech with Bristol-Myers Squibb staff in creating and executing strategies and plans to ensure consistency and efficiency for E2F Decoy's development.

"Tom's project management expertise, including 20 years in pharmaceutical development, will be critical to our company as development of E2F Decoy advances and as we move additional new products from research into development," said John P. McLaughlin, Corgentech's president and chief executive officer. "Under Tom's leadership, Corgentech's alliance management program will work to ensure that the E2F Decoy joint product development program, and other TF Decoy programs, run smoothly and efficiently."

Mr. Yonker was most recently senior director of the project management office at InterMune, where he built processes to enhance early pharmaceutical development design to ensure a project's compatibility with the company's development portfolio. He has designed, upgraded, and implemented sophisticated project and portfolio management organizations and systems at Aviron and ALZA. In addition, Mr. Yonker was instrumental in the leadership of individual development projects in such wide-ranging therapeutic areas as fibrotic, infectious, and psychiatric diseases. During his two-decade career in pharmaceutical development, Mr. Yonker has provided professional project management and drug development expertise to a wide variety of small and large pharmaceutical companies, including Synergen, Glaxo, and The Upjohn Company.

Mr. Yonker has spoken frequently on project management topics in such venues as Project Management Institute, Drug Information Association and International Society for Pharmaceutical Engineering.

Mr. Yonker holds a bachelor of science degree in biomedical science, a master's of business administration from Western Michigan University, and a project management professional certification from the Project Management Institute.

About Corgentech

Corgentech is a biopharmaceutical company engaged in the discovery, development and commercialization of a new class of therapeutics called transcription factor decoys, or TF decoys. We are creating a pipeline of novel therapeutics based on our proprietary TF decoy technology, focused initially on the treatment of cardiovascular disease, inflammatory disease, such as arthritis, and cancer. For more information on the company and its technology, visit www.corgentech.com.

Forward-Looking Statements

This press release contains forward-looking statements, including without limitation all statements related to our clinical trials, product candidates and collaboration with Bristol-Myers Squibb. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "slated," "goal" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon our current expectations. Forward-looking statements involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the progress, timing and results of our clinical trials, intellectual property matters, difficulties or delays in obtaining regulatory approval, manufacturing our lead product candidate, competition from other pharmaceutical or biotechnology companies, our ability to obtain additional financing to support its operations and other risks detailed in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2003. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Corgentech undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

SOURCE Corgentech Inc.

Richard Powers of Corgentech Inc., +1-650-624-9600, or
[email protected]; or Kristin Nash of WeissCom Partners,
+1-415-302-7951, or [email protected], for Corgentech Inc.

http://www.corgentech.com

News Provided by COMTEX